Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial

No abstract is available for this paper.

• Publication year

  2011

• Venue

  British Journal of Psychiatry

• Publication date

  2011-06-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1192/bjp.bp.110.082727PMID 21263010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain

  2010cited by this paper
• Antidepressant response and the serotonin transporter gene-linked polymorphic region.

  2010cited by this paper
• Harnessing the information contained within genome-wide association studies to improve individual prediction of complex disease risk.

  2009cited by this paper
• Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.

  2009cited by this paper
• Moderation of antidepressant response by the serotonin transporter gene

  2009cited by this paper
• SLC6A4 variation and citalopram response

  2009cited by this paper
• GENetic and clinical Predictors Of treatment response in Depression: the GenPod randomised trial protocol

  2008cited by this paper
• Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.

  2007cited by this paper
• Claims of sex differences: an empirical assessment in genetic associations.

  2007cited by this paper
• A Large Case–Control Study of Common Functional SLC6A4 and BDNF Variants in Obsessive–Compulsive Disorder

  2007cited by this paper
• An exploratory test for an excess of significant findings

  2007cited by this paper
• Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance

  2007cited by this paper
• Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients

  2007cited by this paper
• Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

  2007cited by this paper
• Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain.

  2006cited by this paper
• Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

  2006cited by this paper
• Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.

  2006cited by this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• Causation and causal inference in epidemiology.

  2005cited by this paper
• Sequence analysis of the serotonin transporter and associations with antidepressant response.

  2005cited by this paper
• Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test.

  2004cited by this paper
• Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.

  2003cited by this paper
• The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

  2001cited by this paper
• Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

  2001cited by this paper
• Searching for genetic determinants in the new millennium

  2000cited by this paper
• Serotonin transporter (5-HTT) promoter genotype may influence the prolactin response to clomipramine

  2000cited by this paper
• Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis.

  2000cited by this paper
• Power and sample size calculations in case-control studies of gene-environment interactions: comments on different approaches.

  1999cited by this paper
• Bipolar disorder and the serotonin transporter gene: a family-based association study

  1999cited by this paper
• Development and Testing of the UK SF-12

  1997cited by this paper
• Development and testing of the UK SF-12 (short form health survey).

  1997cited by this paper
• Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region

  1996cited by this paper
• Polymorphism in serotonin transporter gene associated with susceptibility to major depression.

  1996cited by this paper
• Assessing psychiatric disorder with a human interviewer or a computer.

  1994cited by this paper
• Measuring psychiatric disorder in the community: a standardized assessment for use by lay interviewers

  1992cited by this paper
• On power and sample size for studying features of the relative odds of disease.

  1990cited by this paper
• [Intravenous versus oral treatment of endogenously depressed patients with doxepin--a double-blind study with plasma level determination].

  1989cited by this paper
• The Hospital Anxiety and Depression Scale.

  1987cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper
• An inventory for measuring depression.

  1961cited by this paper

• Non-adherence in randomised controlled trials: empirical comparison of treatment policy and efficacy estimands using individual participant data

  2026cites this paper
• Pharmacogenetics and the Response to Antidepressants in Major Depressive Disorder

  2025cites this paper
• Sertraline for anxiety in adults with a diagnosis of autism (STRATA): study protocol for a pragmatic, multicentre, double-blind, placebo-controlled randomised controlled trial

  2024cites this paper
• Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

  2021cites this paper
• Treatment resistant depression

  2021cites this paper
• The importance of transdiagnostic symptom level assessment to understanding prognosis for depressed adults: analysis of data from six randomised control trials

  2021cites this paper
• Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial

  2020influential citation
• Depression: Biological markers and treatment

  2020cites this paper
• Quantifying between‐cohort and between‐sex genetic heterogeneity in major depressive disorder

  2019cites this paper
• The involvement of sleep in the relationship between the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and depression: A systematic review.

  2019cites this paper
• What factors indicate prognosis for adults with depression in primary care? A protocol for meta-analyses of individual patient data using the Dep-GP database

  2019cites this paper
• Genetic Testing for Diagnosis and Management of Behavioral Health Conditions Effective : October 1 , 2018

  2018cites this paper
• Genetic Testing for Diagnosis and Management of Mental Health Conditions Policy

  2018cites this paper
• Genetic Testing for Diagnosis and Management of Mental Health Conditions

  2018cites this paper
• Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years

  2017cites this paper
• Genetic Testing for Mental Health Conditions

  2017cites this paper
• Association of 5-HTTLPR Polymorphism with the Nursing Diagnoses and the Achievement of Nursing Outcomes in Patients with Major Depression

  2017influential citation
• association between serotonin transporter polymorphisms (5-hTTlPr) and the MaDrs Dysphoria, retardation, and Vegetative subscale scores in the treatment of depression

  2017cites this paper
• Association between serotonin transporter polymorphisms (5-HTTLPR) and the MADRS Dysphoria, Retardation, and Vegetative Subscale scores in the treatment of depression

  2017cites this paper
• Written in the Genes

  2017cites this paper
• A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial

  2017cites this paper
• A mega-analysis of genome-wide association studies for major depressive disorder

  2016cites this paper
• Genetics as a molecular window into recovery, its treatment, and stress responses after stroke

  2016cites this paper
• FEP Medical Policy Manual

  2016cites this paper
• Evoked Culture and Evoked Nature: The Promise of Gene-Culture Co-Evolution Theory for Sociology

  2016cites this paper
• Fluoxetine associated with thrombocytopenia and treatment with reboxetine: 3 cases.

  2015cites this paper
• Genetic Testing for Mental Health Conditions Policy

  2015cites this paper
• SERT and NET polymorphisms, temperament and antidepressant response

  2015cites this paper
• Moderators of response to cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care.

  2015cites this paper
• Genetic polymorphism in the serotonin transporter gene-linked polymorphic region and response to serotonin reuptake inhibitors in patients with premature ejaculation

  2014cites this paper
• Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study

  2014cites this paper
• Allowing for non-adherence to treatment in a randomized controlled trial of two antidepressants (citalopram versus reboxetine): an example from the GENPOD trial

  2014cites this paper
• Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response.

  2014cites this paper
• Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals

  2014influential citation
• From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment

  2014cites this paper
• Clinical effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatment-resistant depression in primary care: the CoBalT randomised controlled trial.

  2014cites this paper
• Are there meaningful biomarkers of treatment response for depression?

  2014cites this paper
• A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy

  2014cites this paper
• Genome-Based Therapeutic Drugs for Depression ( GENDEP ) study Genetic predictors of antidepressant side effects : A grouped candidate gene approach in the

  2014cites this paper
• YOUTH GENETIC VULNERABILITY TO MATERNAL DEPRESSIVE SYMPTOMS: 5‐HTTLPR AS MODERATOR OF INTERGENERATIONAL TRANSMISSION EFFECTS IN A MULTIWAVE PROSPECTIVE STUDY

  2013cites this paper
• Serotonin Transporter Polymorphism (5-HTTLPR) and Citalopram Effectiveness in Iranian Patients with Major Depressive Disorder

  2013cites this paper
• Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment

  2013cites this paper
• Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy

  2013cites this paper
• A mega-analysis of genome-wide association studies for major depressive disorder

  2013cites this paper
• Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research

  2013cites this paper
• Pharmacogenetics of neural injury recovery.

  2013cites this paper
• Facilitated physical activity as a treatment for depressed adults: randomised controlled trial

  2012cites this paper
• Citalopram versus other anti-depressive agents for depression.

  2012cites this paper
• Genome-wide approaches to antidepressant treatment: working towards understanding and predicting response

  2012cites this paper
• Characterization of serotonin neurotransmission in knockout mice: implications for major depression

  2012cites this paper
• Piccolo genotype modulates neural correlates of emotion processing but not executive functioning

  2012cites this paper
• Severity of depression and response to antidepressants: GENPOD randomised controlled trial

  2012cites this paper
• Stress-related depression: Neuroendocrine, genetic, and therapeutical aspects

  2012cites this paper
• Association between serotonin transporter gene promoter-region polymorphism and 4- and 12-week treatment response to sertraline in posttraumatic stress disorder.

  2012cites this paper
• Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial

  2012cites this paper
• Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy

  2012cites this paper
• The truth about genetic variation in the serotonin transporter gene and response to stress and medication

  2011cites this paper
• Involving patients with depression in research: survey of patients' attitudes to participation.

  2011cites this paper
• Opus: University of Bath Online Publication Store Minimal Clinically Important Difference on the Beck Depression Inventory – Ii According to the Patient's Perspective

  year unknowncites this paper
• Association of the 5-HTT Gene-Linked Promoter Region Association of the 5-HTT Gene-Linked Promoter Region (5-HTTLPR) Polymorphism with Psychiatric Disorders: Review of (5-HTTLPR) Polymorphism with Psychiatric Disorders: Review of Psychopathology and Pharmacotherapy Psychopathology and Pharmacotherap

  year unknowncites this paper
• Opus: University of Bath Online Publication Store Are Multiple Physical Symptoms a Poor Prognostic Factor or Just a Marker of Depression Severity? Secondary Analysis of the Genpod Trial

  year unknowncites this paper